{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T02:05:03Z","timestamp":1794621903878,"version":"4.9.1"},"reference-count":3,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"16","license":[{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,20]]},"DOI":"10.1097\/cm9.0000000000003159","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T16:00:48Z","timestamp":1721232048000},"page":"1991-1992","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of abrocitinib in Chinese patients with moderate-to-severe atopic dermatitis: A post hoc analysis of the JADE REGIMEN phase 3 trial"],"prefix":"10.1097","volume":"137","author":[{"given":"Hang","family":"Li","sequence":"first","affiliation":[{"name":"Department of Dermatology, Peking University First Hospital, National Clinical Research Center for Skin and Immune Diseases, Beijing 100034, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianjin","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Zhejiang Provincial People\u2019s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang 310014, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo A.","family":"Encinas","sequence":"additional","affiliation":[{"name":"Pfizer S.A. de C.V., Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shefali","family":"Vyas","sequence":"additional","affiliation":[{"name":"Pfizer Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Wang","sequence":"additional","affiliation":[{"name":"Pfizer Investment Co., Ltd, Beijing 100010, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Luo","sequence":"additional","affiliation":[{"name":"Pfizer (China) R&D Co., Ltd, Shanghai 201200, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqi","family":"Li","sequence":"additional","affiliation":[{"name":"Pfizer PBG, Shanghai 200041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,7,15]]},"reference":[{"key":"R1-20250602","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.anai.2017.10.039","article-title":"Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape","volume":"120","author":"Boguniewicz","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R2-20250602","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"key":"R4-20250602","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaad.2021.05.075","article-title":"Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN phase 3 trial","volume":"86","author":"Blauvelt","year":"2022","journal-title":"J Am Acad Dermatol"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003159","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T19:02:31Z","timestamp":1748890951000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,15]]},"references-count":3,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000003159","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,15]]},"assertion":[{"value":"2023-10-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}